The Food and Drug Administration (FDA) promulgated a rule prescribing time–temperature–salinity processing parameters for hot-process smoked fish to prevent botulism, particularly from Clostridium botulinum type E associated with certain species such as whitefish. During notice-and-comment, fish processors, public health officials, and other stakeholders submitted comments challenging the scientific assumptions and warning that the specified heat treatment would render some species (notably Great Lakes whitefish) unpalatable or commercially unsaleable. Commenters urged that alternative combinations of salinity, refrigeration, and lower heat could achieve equivalent safety. The FDA finalized the rule with minimal changes, did not disclose the key scientific studies and data on which it relied, and issued a brief statement of basis and purpose that did not substantively address the major comments about feasibility, palatability, or alternatives. When Nova Scotia Food Products processed smoked whitefish using methods not in strict conformance with the regulation, the United States initiated an enforcement action. The district court upheld the regulation and found Nova Scotia in violation. On appeal, Nova Scotia argued that the regulation was procedurally invalid under the APA because the agency failed to disclose its scientific basis and failed to respond to significant comments, making meaningful participation and judicial review impossible.
Did the FDA's informal rulemaking comply with APA § 553 where the agency failed to disclose the scientific data underlying the regulation and did not respond to significant comments regarding feasibility, palatability, and alternative safety measures, such that the rule could properly be enforced against Nova Scotia?
Under APA § 553, an agency engaged in informal rulemaking must: (1) provide adequate notice of the proposed rule and the critical material on which it relies so that affected parties have a meaningful opportunity to comment; and (2) issue a statement of basis and purpose sufficient to enable courts and the public to understand the agency's reasoning, including responses to significant comments and consideration of important alternatives and feasibility concerns. An agency may not base a rule on undisclosed scientific data that deprive interested persons of an opportunity to challenge the assumptions or methodology, and it must address material criticisms to facilitate reasoned decision-making and judicial review.
The Second Circuit held that the FDA's rulemaking did not satisfy APA § 553 because the agency failed to disclose the scientific basis of the rule and failed to respond to significant comments about the rule's feasibility and effects on product palatability. The court therefore set aside enforcement of the regulation against Nova Scotia and remanded for further proceedings consistent with the opinion.
The court emphasized that meaningful notice-and-comment requires that commenters have access to the critical scientific studies, data, and methodologies on which the agency relies. Without disclosure of the underlying evidence, affected parties cannot effectively critique the agency's assumptions, propose alternatives, or build a record for judicial review. The FDA's reliance on undisclosed scientific material, combined with its refusal to identify or summarize the crucial data, rendered participation effectively impossible and frustrated the APA's purposes. The court also found the FDA's statement of basis and purpose inadequate. Multiple commenters—including state health authorities and industry participants—raised serious, technically grounded objections that the mandated heat treatment would make whitefish inedible and that alternative combinations of salinity and refrigeration could achieve equivalent safety. These were not minor points; they went to the heart of the rule's feasibility and its real-world impact. The agency's generalized statements and its assertion that it could not address every comment did not suffice. The APA requires a reasoned explanation that addresses significant comments and explains the basis for rejecting alternatives. The FDA's public health mission did not excuse its failure to consider feasibility and palatability. While the agency may give health and safety primacy, it must still confront record evidence showing that a rule may effectively eliminate a product from the market or that less burdensome, equally protective alternatives exist. Finally, the court rejected the notion that a post-promulgation variance process could substitute for proper rulemaking. A variance mechanism cannot cure the failure to disclose key data or to respond to substantial comments at the time of promulgation.
Nova Scotia is a foundational case on the procedural rigor required in informal rulemaking. It establishes that agencies must disclose the critical scientific material underlying proposed rules, respond to significant comments, and provide a statement of basis and purpose that enables meaningful public participation and judicial review. The decision is frequently cited alongside Portland Cement and, later, State Farm, as part of the doctrine requiring a reasoned explanation and a reviewable record. For law students, the case illustrates how courts police the boundary between deference to agency expertise and the insistence on transparent, participatory, and reasoned administrative process.
United States v. Nova Scotia Food Products stands as a clear directive that agencies must conduct transparent, participatory, and reasoned rulemaking. Even when regulating to protect public health, an agency must disclose the technical basis for its choices and squarely address significant criticisms and alternatives raised during the comment period.